A Study of MEDI9253 in combination with durvalumab in select solid tumors

Trial Identifier: D7880C00001
Sponsor: AstraZeneca
NCTID:: NCT04613492
Start Date: December 2020
Primary Completion Date: May 2024
Study Completion Date: May 2024
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
FR Bordeaux, FR, 33076
FR Lyon, FR, 69373
FR Toulouse, FR, 31100
FR Villejuif, FR, 94800
US, CA La Jolla, CA, US, 92093
US, CA San Francisco, CA, US, 94115
US, CA Santa Monica, CA, US, 90404
US, FL Miami, FL, US, 33136
US, GA Atlanta, GA, US, 30322
US, IA Iowa City, IA, US, 52242
US, MO Saint Louis, MO, US, 63110
US, NC Chapel Hill, NC, US, 27514
US, NC Huntersville, NC, US, 28078
US, NY Buffalo, NY, US, 14263
US, NY New York, NY, US, 10032
US, NY New York, NY, US, 10065
US, PA Pittsburgh, PA, US, 15232
US, RI Providence, RI, US, 02903
US, SC Greenville, SC, US, 29605
US, WA Seattle, WA, US, 98109